Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
ADMA Biologics (ADMA) has shared an update.
Kaitlin Kestenberg has been promoted to Chief Operating Officer and Senior Vice President, Compliance at ADMA Biologics, Inc., effective April 1, 2024. Bringing a wealth of experience from her previous roles at the company and her work at Acorda Therapeutics and Merck & Co., Kestenberg is well-prepared for her new responsibilities. Her employment agreement includes a competitive salary, bonus eligibility, and severance benefits, alongside stock options and restricted stock units, ensuring her interests are aligned with the company’s growth and success. This strategic move signals ADMA Biologics’ commitment to reinforcing its leadership team and positions Kestenberg as a key player in driving forward the company’s operational and compliance strategies.
See more data about ADMA stock on TipRanks’ Stock Analysis page.
